Advanced search
Publication Cover
The American Journal of Drug and Alcohol Abuse
Encompassing All Addictive Disorders
Volume 5, 1978 - Issue 2
Submit an article Journal homepage
7
Views
3
CrossRef citations to date
0
Altmetric
Original Article

Naltrexone and Conventionality

Frederic Suffet Multitrack Abstinence Program New York Medical College 5 East 102nd Street New York, New York, 10029
,
Daniel C. Remine Multitrack Abstinence Program New York Medical College 5 East 102nd Street New York, New York, 10029
,
Elizabeth Taleporos Multitrack Abstinence Program New York Medical College 5 East 102nd Street New York, New York, 10029
&
Richard Brotman Multitrack Abstinence Program New York Medical College 5 East 102nd Street New York, New York, 10029
Pages 221-233 | Published online: 07 Jul 2009

References

  • Schecter A. Clinical use of naltrexone (EN 1639 A), Part II: Experience with the first 50 patients in a New York City clinic. Am. J. Drug Alcohol Abuse 1975; 2: 433–442
  • Curran S., Savage C. Patient response to naltrexone: Issues of acceptance, treatment effects, and frequency of administration. Narcotic Antagonists: Naltrexone (Research Monograph 9), D. Julius, P. Renault. National Institute on Drug Abuse, Washington, D.C. 1976; 67–76
  • Lewis D., . Use of narcotic antagonists (naltrexone) in an addiction treatment program. Narcotic Antagonists: Naltrexone (Research Monograph 9), D. Julius, P. Renault, et al. National Institute on Drug Abuse, Washington, D.C. 1976; 99–105
  • Landsberg R., . An analysis of naltrexone-Its efficacy, safety and potential. Narcotic Antagonists: Naltrexone (Research Monograph 9), D. Julius, P. Renault, et al. National Institute on Drug Abuse, Washington, D.C. 1976; 106–113
  • Bradford A., . Interim report on clinic safety data collected from 17 NIDA- funded naltrexone studies. Narcotic Antagonists: Naltrexone (Research Monograph 9), D. Julius, P. Renault, et al. National Institute on Drug Abuse, Washington, D.C. 1976; 163–171
  • Goldstein A. On the role of chemotherapy in the treatment of opiate addiction. Am. J. Drug Alcohol Abuse 1975; 2: 279–288
  • O'Brien C., et al. Clinical experience with naltrexone. Am. J. Drug Alcohol Abuse 1975; 2: 365–377
  • Brahen L. Naltrexone study guidelines: Good vehicle-Wrong destination. Am. J. Drug Alcohol Abuse 1975; 2: 451–453
  • Resnick R., . Clinical efficacy of naltrexone: A one year follow-up. Narcotic Antagonists: Naltrexone (Research Monograph 9), D. Julius, P. Renault, et al. National Institute on Drug Abuse, Washington, D.C. 1976; 114–117
  • Haas N., . Naltrexone in methadone patients electing to become “drug free,”. Narcotic Antagonists: Naltrexone (Research Monograph 9), D. Julius, P. Renault, et al. National Institute on Drug Abuse, Washington, D.C. 1976; 70–73
  • Meyer R., . Limitations of an extinction approach to narcotic antagonist treatment. Narcotic Antagonists: Naltrexone (Research Monograph 9), D. Julius, P. Renault, et al. National Institute on Drug Abuse, Washington, D.C. 1976; 123–133
  • Hurzeler M., Gerwirtz D., Kleber H. Varying clinical context for administering naltrexone. Narcotic Antagonists: Naltrexone (Research Monograph 9), D. Julius, P. Renault. National Institute on Drug Abuse, Washington, D.C. 1976; 48–66
  • Resnick R., Fink M., Freedman A. A cyclazocine typology in opiate dependence. Am. J. Psychiatry 1970; 126: 1256–1260
  • Callahan E., . Comparison of two naltrexone treatment programs: Naltrexone alone versus naltrexone plus behavior therapy. Narcotic Antagonists: Naltrexone (Research Monograph 9), D. Julius, P. Renault, et al. National Institute on Drug Abuse, Washington, D.C. 1976; 150–157
  • Resnick R., et al. Naloxone-precipitated withdrawal: A method for rapid induction onto naltrexone. Clin. Pharmacol. Ther 1977; 21: 409–413
  • Brotman R., Freedman A. Continuities and Discontinuities in the Process of Patient Care for Narcotic Addicts. Health Research Council, New York 1965; 190–222

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.